We are requesting a 5-year competing renewal of our NIDA P30 Center with support for the 6 current Cores (Administrative, Animal, Biochemical Pharmacology, Cell and Immunology, Integrative Pharmacology, and Molecular Biology) and the addition of a seventh, the Database and Drug Interactions Core. Since its inception, the P30 Center has enhanced productivity, synergy, and multidisciplinary research, and enabled the recruitment of new faculty into the field of drugs of abuse. Major integrative themes of our Center include 1) Neuroimmunopharmacology including the study of the effects of drugs of abuse on HIV, 2) Study of drugs of abuse, particularly opioids and cannabinoids, in regulation of inflammation, pain, body temperature, reinforcement, and immune function, and 3) Drug interaction studies which are vital because individuals rarely abuse a single drug. New directions include increased emphasis on cannabinoids and additional studies on the relationship between drugs of abuse and HIV. The scope of the ongoing and future projects in the Center marries in vivo and in vitro approaches that examine effects of drugs at the cellular, biochemical, molecular and whole-organism levels. Integration of information ranging from measurements of behavior to gene activation has stimulated collaborations leading to novel hypotheses and results. The Cores of the P30 Center have fostered multidisciplinary interactions resulting in a true intellectual integration and synergy leading to hypothesis building and implementation of lines of experimentation not previously conceived. The results from the collaborative studies supported by the P30 Cores have been truly innovative. The Center also is a focus for training students, postdoctoral fellows, and junior faculty. Temple University has made major commitments to the Center that will sustain growth in the area of drug abuse research in the future. The Center is the glue that brings together investigators currently funded by NIH or other Federal or non-Federal sources and enhances and extends the effectiveness of research related to drug abuse and addiction in a cost-efficient manner. Cutting edge research being conducted by members of CSAR is supported and enhanced by utilizing the expertise, methodologies, and techniques provided by the Cores.

Public Health Relevance

Drug abuse and addiction continue to be a major public problem with enormous personnel, societal and public health costs. The goal of the P30 Center is to provide cutting-edge resources for investigators to study the impact of drugs of abuse on physiological and pathological processes. The core facilities will enhance and expand the scope of research on drugs of abuse, thus facilitating important scientific discoveries with the overall aim of reducing drug abuse and formulating new important therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA013429-14
Application #
8462580
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Program Officer
Purohit, Vishnudutt
Project Start
2000-09-30
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
14
Fiscal Year
2013
Total Cost
$1,180,557
Indirect Cost
$393,519
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Brailoiu, G Cristina; Deliu, Elena; Console-Bram, Linda M et al. (2016) Cocaine inhibits store-operated Ca2+ entry in brain microvascular endothelial cells: critical role for sigma-1 receptors. Biochem J 473:1-5
Nayak, Sunil; Roberts, Adam; Bires, Kristofer et al. (2016) Benzodiazepine inhibits anxiogenic-like response in cocaine or ethanol withdrawn planarians. Behav Pharmacol 27:556-8
Reichenbach, Zachary Wilmer; Li, Hongbo; Ward, Sara Jane et al. (2016) The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia. Neurosci Lett 630:9-15
Park, Soonhong; Ahuja, Malini; Kim, Min Seuk et al. (2016) Fusion of lysosomes with secretory organelles leads to uncontrolled exocytosis in the lysosomal storage disease mucolipidosis type IV. EMBO Rep 17:266-78
Hudry, E; Martin, C; Gandhi, S et al. (2016) Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther 23:380-92
Meza-Aviña, Maria Elena; Lingerfelt, Mary A; Console-Bram, Linda M et al. (2016) Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorg Med Chem Lett 26:1827-30
Cornwell, William D; Wagner, Wendeline; Lewis, Mark G et al. (2016) Effect of chronic morphine administration on circulating dendritic cells in SIV-infected rhesus macaques. J Neuroimmunol 295-296:30-40
Holliday, Erica D; Nucero, Paul; Kutlu, Munir G et al. (2016) Long-term effects of chronic nicotine on emotional and cognitive behaviors and hippocampus cell morphology in mice: comparisons of adult and adolescent nicotine exposure. Eur J Neurosci :
Persidsky, Yuri; Hill, Jeremy; Zhang, Ming et al. (2016) Dysfunction of brain pericytes in chronic neuroinflammation. J Cereb Blood Flow Metab 36:794-807
Gregg, Ryan A; Hicks, Callum; Nayak, Sunil U et al. (2016) Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator. Neuropharmacology 108:111-9

Showing the most recent 10 out of 287 publications